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ABSTRACT 
Short interfering RNAs (siRNAs) have engendered much enthusiasm for their ability to silence 
expression of specific genes. However, it is now well established that siRNAs, depending on 
their sequence, can be variably sensed by the innate immune system through recruitment of toll-
like receptors 7 and 8 (TLR7/8). Here we aimed to identify sequence-based modifications 
allowing for the design of bifunctional siRNAs with both pro-inflammatory and specific silencing 
activities, and with potentially increased therapeutic benefits as antiviral or antitumor agents. We 
found that the introduction of a micro-RNA-like non-pairing uridine-bulge in the passenger 
strand robustly increased immunostimulatory activity on human immune cells. This sequence 
modification had no effect on the silencing efficiency of the siRNA. Increased 
immunostimulation with the uridine-bulge design was specific to human cells, and conserved 
silencing efficiency required a Dicer-substrate scaffold. The increased cytokine production with 
the uridine-bulge design resulted in enhanced protection against Semliki Forest virus infection, in 
viral assays. Thus, we characterize for the first time a design scaffold applicable to any given 
siRNA sequence, that results in increased innate immune activation without affecting gene 
silencing. This sequence coupled with structural modification differentially recruits human TLR8 
over TLR7, and could have potential application in antiviral therapies.  
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INTRODUCTION 
RNA interference (RNAi) is an evolutionarily conserved antiviral mechanism that relies on short 
molecules of double-stranded RNA (dsRNA) of 21-23 base pairs (bp), known as short interfering 
RNAs (siRNAs). Among species, the hallmark of RNAi is its specificity, affecting only the 
expression of the target gene sharing perfect homology with the siRNA sequence. Several 
siRNAs targeting disease-causing genes are currently in clinical trials, and the therapeutic 
potential of these double-stranded oligoribonucleotides is extensive.1 However, we and others 
have shown that siRNAs can be sensed by the mammalian immune system, compromising the 
specificity of silencing.2-4 In addition to the recognition of low-molecular-mass synthetic agonists 
such as imidazoquinolines, toll-like receptors 7 and 8 (TLR7/8) can sense single-stranded RNAs 
(ssRNAs) and siRNAs in a sequence-specific manner.2, 3, 5 Recent publications indicate that short 
RNAs can be differentially sensed by TLR7 and TLR8, according to their sequence.6, 7 The 
expression of these receptors is restricted to certain blood immune cell subtypes, including 
human plasmacytoid dendritic cells (pDCs) which express the highest levels of TLR7, and human 
monocytes/macrophages which express the highest levels of TLR8.8 Systemic delivery of siRNA 
in vivo is intrinsically related to a potential recruitment of these immune cells, as both TLR7 and 
8 are located in the endosomal compartment and can sense endocytosed ssRNA/dsRNA.9 TLR7 
activation in pDCs preferentially induces interferon-α (IFN-α) production, whereas TLR8 
activation in monocytes/macrophages results in production of tumor necrosis factor-α (TNF-α) 
and interleukin-12(p70) (IL-12(p70)).10  
While immune activation caused by siRNAs was unanticipated and is a cause of  
concern,11 backbone modifications have been developed that dampen activation of an immune 
response.12-14 However, we have previously proposed that it might be therapeutically beneficial to 
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design siRNAs that provoke an enhanced immune response and enhance siRNA-mediated 
antiviral and antitumor therapy.11 Indeed, proof of principle of a “bifunctional” siRNA approach 
of combining gene silencing and immunostimulation demonstrating antitumoral synergy between 
innate immune recruitment and gene-specific targeting has recently published.15 However, this 
study relied on a 5’-triphosphate modification of siRNA and activation of innate immunity via 
retinoic acid-inducible gene I (RIG-I).15 
To date, there are several reports that certain motifs in siRNA duplexes specifically 
induce TLR7/8,2, 3 and detailed studies of 19-21 nucleotide (nt) single-stranded RNAs have 
identified different motifs that promote TLR7/8 recruitment (6, European patents EP1764107 and 
EP1764108). While useful, determination of immunostimulatory motifs in each individual strand 
of an siRNA is a poor predictor of the immunostimulatory potential of the resulting duplex (4, 16 
and Gantier and Williams, unpublished). Importantly, rational design of efficient siRNAs remains 
predictive, and in most cases only a few siRNAs can be confirmed to promote strong silencing. 
Selection of siRNAs based on criteria of both RNAi efficiency and sequenced-based 
immunostimulatory potential may compromise one or other parameter. To our knowledge, there 
is currently no modification described that can be applied to a given siRNA duplex to increase its 
ability to recruit TLR7/8 without impacting on its gene silencing efficiency. Here we characterize 
a micro-RNA (miRNA)-like sequence modification that robustly increases immunostimulation of 
three independent Dicer-substrate siRNAs (D-siRNAs). This modification did not impact on 
silencing efficiency of the duplexes, and likely involves specific TLR8 recruitment. 
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RESULTS 
Structural/sequence requirements of short RNAs for TLR7/8 activation 
We and others have previously demonstrated that TLR7/8 sensing of short RNAs is uridine 
dependent.5, 7, 17 However, our previous findings also indicated that the position of the uridine 
residues within the secondary structure of an ssRNA could impact on immunostimulation.7 To 
further characterize the impact of secondary structure of ssRNAs on TLR7/8 recruitment, we 
used a rational approach to increase the predicted self-complementarity of an ssRNA previously 
shown to activate both IFN-α and TNF-α in human peripheral blood mononuclear cells 
(PBMCs), without affecting its uridine content (B-406-AS 7) (Fig. 1a and Table 1). Increasing the 
secondary structure did not significantly affect IFN-α, but it strongly impacted on the TNF-α 
induction profile in human PBMCs (>2-fold increase for B-406AS-1 and B-406AS-2 compared 
to B-406AS, Figs. 1a and b). Surprisingly, restriction of the 5 nt loop of B-406AS-2 to a 3 nt loop 
(see B-406AS-3) ablated the TNF-α induction seen in B-406AS-2. Taken together, these results 
suggested that TLR8 (as measured through TNF-α production) was more sensitive to the 
secondary structure of an ssRNA than TLR7 (measured through IFN-α production). In parallel, 
we also assessed the net impact of uridine content in an ssRNA with low self-secondary structure, 
independent of structure variation (Fig. 1c and Table 1). In accord with uridine-dependent 
TLR7/8 sensing, both IFN-α and TNF-α were induced in a dose-dependent manner with 
increasing uridines (Fig. 1d, compare ss41-N and ss41-4/6/8/10).  At the doses of ssRNA used 
(90 nM), a minimum of four uridines was required to detect immunostimulation (see ss41-4, for 
TNF-α), consistent with our previous observations (see SC and SB ssRNAs 7).  However, more 
than eight uridines did not result in any further increase in cytokine production (compare ss41-8 
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and ss41-10, for IFN-α and TNF-α, Fig. 1d).  Collectively, these results support a role for both 
uridine content and secondary structure in TLR7/8 sensing of ssRNAs. 
 
Rational design of immunostimulatory siRNAs 
To study the impact of uridine content and secondary structure of siRNA duplexes on both 
immunostimulation and silencing efficiency, we used a rational approach affecting the sequence 
of siRNA duplexes. While siRNAs are conventionally designed as 21-23 bp duplexes to mimic 
Dicer products, it has been shown that dsRNAs that are long enough to be treated as Dicer 
substrates (D-siRNAs) can also promote RNAi in mammalian cells.18, 19 Further, using an 
asymmetric D-siRNA of 25/27 nt with both blunt and 3’ overhang ends helps to mimic the 
natural substrates of mammalian Dicer (i.e. pre-miRNA hairpins) and allows for increased 
directional processing and selection of the guide strand of the siRNA.18, 19 The 3’ end of an 
asymmetric D-siRNA (using the passenger strand as a reference) is preferentially cleaved by 
Dicer and should have little impact on sequence-specific silencing.18 Accordingly, a set of three 
D-siRNAs was synthesized with increased uridines in the region predicted to be cleaved by Dicer 
(siLam-1, siLam-2, siLam-3, Fig. 2a). Noting that TLR8 may be sensitive to the secondary 
structure of ssRNAs (Fig. 1), we designed a Dicer substrate with a miR-29a-like uridine-bulge on 
the passenger strand (position 9-12), predicting that this modification would not alter Dicer 
processing and strand selection (siLam-4, Fig. 2a). These siRNAs were derived from a previously 
validated D-siRNA sequence targeting the human LaminA/C  (LMNA) mRNA (M. Behlke, 
unpublished). Unexpectedly, when assayed for immunostimulation in human PBMCs, a decrease 
in IFN-α and/or TNF-α levels with siLam-1 and siLam-2 was observed when compared to the 
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native siLam control (Fig. 2b). Nevertheless, both siLam-3 and siLam-4 promoted a significant 
increase in IFN-α and/or TNF-α production. In HEK 293T cells, siLam-2 and siLam-4 both 
silenced LaminA/C mRNA expression with equal efficacy to the control sequence, but the other 
approaches were less effective (Fig. 2c). siLam-4 silencing efficacy was confirmed by measuring 
LaminA/C mRNA silencing by siLam-4 compared to  control siLam-N in dose-response 
experiments (at 10 nM, 2 nM and 0.4 nM), where no significant differences were observed (not 
shown). These results indicated that the addition of an miRNA-like uridine-bulge to a D-siRNA 
scaffold resulted in increased immunostimulation without affecting RNAi activity. 
 
Validation of the uridine-bulge siRNA design 
In order to validate that the previous observations made with the siLam-4 design could be 
reproduced independently of the sequence of the duplex/target chosen, a D-siRNA targeting the 
enhanced green fluorescent protein (EGFP) was selected using the siRNA design software 
BIOPREDsi.20 From the five best hits suggested by BIOPREDsi, the duplex with the least 
number of uridine residues was selected to minimize the basal immunostimulatory activity of the 
siRNA, and 6 nt complementary to the EGFP target added to make it a D-siRNA (Fig. 3e). When 
comparing this EGFP D-siRNA with (siEGFP-U) or without (siEGFP) the bulge modification in 
immunostimulatory assays, a strong increase in TNF-α induction (>10 fold at 500 and 750 nM) 
and a significantly higher induction of IFN-α (at 500 nM) with the uridine-bulge modification 
was observed (Fig. 3a). In addition, the uridine-bulge did not affect the ability of the EGFP D-
siRNA to trigger RNAi in HEK 293T cells stably expressing EGFP (Fig. 3b). Similar results 
were seen with another D-siRNA target, the E6/E7 oncogene of the Human Papilloma Virus 16 
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(Figs. 3c, d and e, compare siE6/E7 and siE6/E7-U). Collectively, these results support the 
findings that independent of the D-siRNA sequence, the uridine-bulge design robustly increases 
TNF-α and IFN-α induction in human PBMCs, without altering the ability of the D-siRNA to 
enter the RNAi pathway. 
 
Uridine-bulge sensing is not conserved between human and mouse 
The preferential induction of TNF-α over IFN-α with the uridine-bulge modification of all D-
siRNAs suggested a predominant role for monocytes in sensing the bulge. To better define the 
immune cell subtype involved in the sensing of the modification, the ability of isolated CD14+ 
monocytes to respond to the uridine-bulge of siEGFP-U was assessed (Fig. 4a). As anticipated, a 
significantly increased production of TNF-α was observed with the uridine-bulge D-siRNA 
(siEGFP-U) (>15 fold) in these cells. We have recently reported that human monocytic cells 
sense short RNAs through both TLR7 and TLR8 recruitment.7 To further characterize the 
respective involvement of both receptors in the sensing of the uridine-bulge modification, we 
used mouse bone marrow derived macrophages (BMMs), in which ssRNA/siRNA sensing 
exclusively relies on TLR7 due to the lack of mouse TLR8 response to RNA agonists.2, 5, 7 
Unexpectedly, the uridine-bulge modification inhibited rather than promoted the 
immunostimulatory effect of the siEGFP D-siRNA, as measured by TNF-α production (Fig. 4b). 
While this implicates human TLR8 in sensing of the uridine-bulge modification, it precludes 
using murine-based disease models to measure potential therapeutic benefits of the uridine-bulge 
modification. 
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Pro-inflammatory/antiviral effects of uridine-bulge modification 
We next looked to elucidate the cytokine profile induced by the uridine-bulge modification of the 
three D-siRNAs (siLam-4, siEGFP-U and siE6/E7-U) in human PBMCs. Multi-cytokine protein 
array analysis of 17 cytokines confirmed significant up-regulation of the pro-inflammatory 
cytokines TNF-α, IFN-γ, IL-1β, and IL-12(p70) (Fig. 5). In addition, IL-4, IL-5, IL-7, IL-10, IL-
17, G-CSF and GM-CSF were also significantly induced in at least two of the three D-siRNAs 
analyzed (not shown). Notably, both the IL-6 and IL-8 values were outside the linear range of the 
standard curve and were not accurately assessed. Since there was increased induction of type I 
and II IFNs by the uridine-bulge modification, the antiviral effects of the modified siEGFP D-
siRNAs were assessed. Conditioned media from PBMCs treated overnight with the EGFP D-
siRNAs was used to treat Hela cells prior to infection with Semliki Forest virus (SFV) and Hela 
cell survival was subsequently assayed (Materials and Methods). As expected from the higher 
IFN-α production (Fig. 3), the results showed that the uridine modification of siEGFP-U 
conferred significant protection to viral infection compared to the native siEGFP D-siRNA (Fig. 
6). 
 
Use of uridine-bulge modification with 21 bp siRNA scaffold 
siβ-Gal-924 is a 21 bp siRNA duplex targeting the β-galactosidase mRNA, demonstrating 
silencing efficiency but low immunostimulatory potential in human PBMCs.3 To define whether 
the uridine-bulge modification could also be applied independently of the Dicer-substrate 
scaffold, we synthesized siβ-Gal-924 and its uridine-bulge variant (siβ-Gal-924-U, 
Supplementary Table S1) and tested for immunostimulation and down-regulation efficiency. In 
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agreement with our previous results, the uridine-bulge modification of siβ-Gal-924 promoted 
significant induction of TNF-α and IFN-α in human PBMCs, compared to its native variant (Fig. 
7a). Nevertheless, in HEK 293T cells transiently expressing β-galactosidase, the down-regulation 
efficiency of siβ-Gal-924 was reduced (~10%) by the uridine-bulge modification, indicating an 
adverse effect of the modification on RNAi recruitment (Fig. 7b). Of note, siβ-Gal-478 promoted 
stronger down-regulation of β-galactosidase than siβ-Gal-924, as previously reported.3 
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DISCUSSION 
The innate immune system is the first line of defense against infection with viruses or pathogens. 
Sensing of specific pathogen-associated molecular patterns (PAMPs) by innate immune receptors 
such as the TLRs, is followed by the induction of a targeted response limiting the infection. As 
key mediators of this response, IFNs coordinate the expression of hundreds of antiviral genes.21 
For this reason, IFNs are commonly used in the treatment of hepatitis C (HCV) or chronic 
hepatitis B virus (HBV) infection.22, 23 Recruitment of TLR7 or both TLR7 and 8 by synthetic 
agonists (such as isatoribine and resiquimod) potently induces IFNs, and reduces HCV plasma 
virus concentration.24  
The use of siRNAs or RNAi-based therapies in the treatment of chronic viral infections 
such as immunodeficiency virus type 1 (HIV-1), HCV and HBV is currently under intense 
scrutiny and promises to overcome the limitations of currently available treatments.25-27 Given 
that IFNs are antiviral, it is reasonable to assume that in certain viral infections a strategy aimed 
at recruiting TLR7/8 together with specific gene silencing could have a therapeutic effect on viral 
clearance.27 In support of this, two groups have recently demonstrated the antiviral effects 
promoted by sequence-specific siRNA recruitment of TLR7 in murine models of Influenza 
infection.28, 29 In addition, dual recruitment of antiviral RNAi and TLR7/8 by siRNAs can be 
achieved in vivo, as shown by Morrissey et al.30  This group demonstrated RNAi-driven specific 
reduction of HBV replication, together with a TLR7-driven antiviral response with the same 
siRNA-lipid delivery system.30  
In this work, we sought to develop siRNAs with enhanced immunostimulatory potential 
via TLR7/8 activation. The finding that TNF-α but not IFN-α was strongly induced when self-
12 
complementarity was added to a single-stranded short RNA in human PBMCs (Fig. 1b), led us to 
speculate that TLR7 and TLR8 sensing of short RNAs is governed by a different sensing of 
secondary structures. Further, the observation that the introduction of an miRNA-like uridine-
bulge in the middle of an siRNA duplex consistently induced increased immunostimulation in 
human monocytes (Fig. 4a) but not in mouse macrophages (Fig. 4b), suggests that human TLR8 
and not TLR7, is the sensor of the uridine-bulge modification. In agreement with this, a recent 
study by Ablasser et al. showed a TLR8-activation-dependent increase in production of IL-
12(p70), following  introduction of mismatches in the strands of an siRNA duplex.10 
Unexpectedly, the introduction of additional uridines in the 3’ end of a D-siRNA (using the 
passenger strand as reference) decreased immunostimulation when the Watson-Crick base pairing 
was conserved (Fig. 2, siLam-1 and siLam-2). Nonetheless, the loose secondary structure of this 
5’ end region with G:U wobble pairing resulted in increased TNF-α, independent of IFN-α (Fig. 
2, siLam-3). Whilst confirming a role for uridines in TLR7/8 sensing (Fig. 1), our results 
emphasize that the immunostimulatory potential of an siRNA duplex cannot be accurately 
predicted through sequence analysis. In support of our findings, a screen of 207 siRNAs for 
TLR7/8 stimulation in human PBMCs recently suggested that in addition to uridine content, 
decreased strength of hybridization between the two complementary strands of an siRNA duplex 
positively correlated with increased immunostimulatory activity.31 The results from our three 
distinct siRNA duplexes are unequivocal: addition of the uridine-bulge promotes increased TNF-
α, IFN-γ, IL-1β, and the Th1 polarizing IL-12(p70) (Fig. 5). However, we also observed possible 
saturation in the immunostimulation conferred by the uridine-bulge with one siRNA sequence 
exhibiting high basal immunostimulatory potential (Supplementary Fig. S1 – compare siEGFP-U 
500 nM and siBcl2l12-N 250 nM). Based on these results, we propose that the addition of the 
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uridine-bulge modification will increase pro-inflammatory activation of any given siRNA 
sequence that is not already strongly immunostimulatory, most likely through human TLR8. 
The measurement of both mRNA and protein levels of targeted genes indicated that while 
the uridine-bulge did not impact on the silencing efficiency of any of the Dicer-substrate siRNAs 
studied (Figs. 2c, 3b and 3d), it significantly inhibited RNAi when used in the context of a 21 bp 
siRNA scaffold (Fig. 7b). Relying on the consistent observation that the bulge did not alter 
silencing on three different D-siRNAs, it is unlikely that the difference observed with the shorter 
β-galactosidase uridine-siRNA is simply related to this particular sequence. Because the two 
scaffold designs compared here differ only from one another by their position in the Dicer 
processing step (i.e. upstream or downstream of Dicer), it can be speculated that Dicer processing 
and direct recruitment of the bulge-siRNA is required for correct unwinding and RNA induced 
silencing complex (RISC) loading of the imperfect miRNA-like siRNA duplex. However, it 
could also be argued that the lower affinity of the two strands destabilizes the 21 bp bulge β-
galactosidase siRNA duplex and renders it more prone to degradation, while the longer 
conformation of the D-siRNAs would confer protection. Our observation that the bulge 
modification of the D-siRNAs did not affect RNAi efficiency when compared to a perfectly 
pairing duplex was unexpected. It is currently thought that perfectly pairing duplexes undergo 
Ago2 processing of the passenger strand,32 while miRNA-like imperfect duplexes would be 
unwound through an elusive helicase.33 The finding that similar RNAi efficiency can be achieved 
regardless of the affinity of the two strands of a D-siRNA highlights the concept that Ago2-RISC 
cleavage efficiency of the complementary target is not affected by the nature of the prior 
degradation or unwinding of the passenger strand of the duplex, when Dicer is involved in active 
RISC formation. Further in-depth investigations of the role of Dicer in the recruitment of RNAi 
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by bulge-modified siRNAs with the two scaffold designs should help better characterize the 
previous findings, and could be informative in the design of better miRNA mimics. 
SFV is a single-stranded positive-sense Alphavirus that induces apoptosis of continuously 
cultured cells 24-48 hours after infection.34 SFV is particularly sensitive to IFN pre-treatment of 
cells prior to infection.35 Here we found that conditioned media from human PBMCs treated with 
a uridine-bulge D-siRNA conferred increased protection to SFV infection of Hela cells, when 
compared to a perfect D-siRNA duplex (Fig. 6). This can be attributed to IFN-α production by 
the PBMCs and demonstrates that the increased immunostimulatory potential conferred by the 
uridine-bulge modification can have potent antiviral benefits. However, because the increased 
immunostimulatory effects of the uridine-bulge were not reproduced in mouse due to mouse 
TLR8 unresponsiveness to ss/siRNAs 5), we were unable to further characterize the benefits of 
the uridine-bulge modification in vivo. 
In conclusion, we provide here the first rational design of a bifunctional D-siRNA 
scaffold, which can be applied to any given siRNA sequence. We demonstrate that the addition 
of an miRNA-like uridine-bulge to a Dicer substrate siRNA duplex confers increased 
immunostimulation in human PBMCs, with potential protective effect in viral infection. The 
bulge modification does not compromise RNAi recruitment and target-specific down-regulation, 
when used in a D-siRNA scaffold. Our data is indicative of a TLR8-preferential recruitment of 
short RNAs with loose secondary structure, including D-siRNAs with the uridine-bulge 
modification. Because it relies on a sequence modification, the uridine-bulge strategy presented 
in this work could be immediately amenable to large-scale industrial production of 
oligoribonuclotides, unlike other proposed modifications such as the 5’-triphosphate.15 Combined 
target-specific delivery of bifunctional uridine-bulge D-siRNAs together with macrophage uptake 
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could therefore have therapeutic benefits in the treatment of viral infections and potentially other 
diseases, including cancer. 
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MATERIALS AND METHODS 
Cell isolation and culture. Fresh blood from healthy male donors was collected in heparin-
treated tubes and PBMCs separated by ficoll-paque plus (#17-1440-02, GE Healthcare, 
Rydalmere, Australia) gradient purification, and plated in a 96-well plate at 2x105 cells per well 
in RPMI 1640+L-glutamine medium (#11875085, Invitrogen Corporation, Carlsbad, CA) 
complemented with 1x antibiotic/antimycotic (#15240062, Invitrogen Corporation) and 10% fetal 
bovine serum (#FBS-500, ICPBio Ltd, Auckland, New Zealand) (referred to as complete RPMI), 
as previously reported.7  For the purification of CD14+ monocytes, flow cytometric sorting of 
PBMCs was carried out using anti-CD14-PE (#555398, BD Biosciences, San Jose, CA) as 
previously reported.36 HEK 293T cells and their GFP stable variant (gift from A. Sadler, Monash 
Institute of Medical Research, Melbourne, Australia), were cultured in complete DMEM 
(#11965-092; Invitrogen Corporation)   supplemented with 10% sterile FBS and 1x 
antibiotic/antimycotic. TC-1 cells, a murine fibroblast cell line expressing the human papilloma 
virus 16 (HPV), were grown in complete DMEM. 
 
Isolation of bone marrow macrophages. Mice were housed at the Monash animal facility 
(Monash University, Clayton campus, Australia) and approved under MMCA2007/07. Femurs 
were collected and flushed with RPMI, and cells were plated in complete RPMI supplemented 
with 20% L929-cell conditioned medium on 10 cm bacteriological plastic plates for 7 days at 
37°C in a 5% CO2 atmosphere. 
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Cell stimulation. All siRNA duplexes were synthesized as single-stranded RNAs by Integrated 
DNA Technologies (IDT) with HPLC purification, and resuspended in duplex buffer (100 mM 
potassium acetate, 30 mM HEPES, pH 7.5, DNase–RNase free H2O) to a concentration of 80 
µM.  ssRNAs were annealed to form siRNA duplexes at 92°C for 2 minutes and left for 30 
minutes at room temperature before aliquoting (giving a final concentration of 40 µM). 3M-002 
(human TLR8 agonist and mouse TLR7 agonist 7) (#tlrl-c75) and ODN2216 (TLR9 agonist) 
(#tlrl-hodna) were purchased from Invivogen (San Diego, CA) and used at a final concentration 
of 1 µg/ml and 3 µM, respectively. For immunostimulation assays in PBMCs, CD14+ cells and 
BMMs, ss/siRNAs were transfected with DOTAP (#1811177, Roche, Nutley, NJ), as previously 
reported.7 Transfections were carried out in biological triplicate in all experiments. The ratios of 
DOTAP to ss/siRNA were as follows: 5.3 µg/µl of 80 µM ssRNA (Figs. 1a and b) and 1.87 µg/µl 
of 40 µM siRNA (Figs. 2, 3, 4, 5 and 7). When dose-response experiments were carried out, the 
ratio of siRNA to DOTAP was kept constant. 
 
RNA interference by reverse transfection. For Figs. 3b and 7b, 1.35 µl Lipofectamine 2000 
(#11668; Invitrogen Corporation) was diluted in 150 µl of Opti-MEM (#51985-034; Invitrogen 
Corporation), and 1.5 µl of siRNA molecules (diluted to 4 µM in duplex buffer or freshly in Opti-
MEM) was added such that the final concentration of siRNA in each well was 10 nM. After 20 
minutes of incubation, 50 µl of the Lipofectamine 2000/siRNA/OptiMEM mixture was added 
directly into each well of a 96-well plate (in triplicate). Approximately 15,000 HEK 293T-GFP 
cells suspended in 150 µl of antibiotic-free DMEM (supplemented with 10% FBS) was added to 
each well, giving a final volume of 200 µl per well. For Figs. 2c and 3d, 4.5 µl of Lipofectamine 
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2000 was diluted in 300 µl of Opti-MEM and 4.5 µl of siRNA molecules (diluted to 4 µM in 
duplex buffer or freshly in Opti-MEM) was added such that the final concentration of siRNA in 
each well was 10 nM. After 20 minutes of incubation, 50 µl of the mix was added directly into 
each well of a 24-well plate (in triplicate). 100,000 HEK 293T cells or TC-1 cells resuspended in 
500 µl of antibiotic-free DMEM (supplemented with 10% FBS) was added to each well giving a 
final volume of 600 µl per well. For the Mock condition, no siRNA was added to the 
Lipofectamine mix, while for the Medium condition, OptiMEM only was added to the wells (i.e. 
no Lipofectamine or siRNA was added). siControl is a non-targeting siRNA control (#4635, 
Ambion, Austin, TX), and siGFP19+2 is a published 21 bp siRNA molecule previously shown to 
down-regulate EGFP expression.4 
 
Real-time RT-PCR. cDNA was synthesized from column-purified RNA (NucleoSpin RNAII 
columns, #740955, Macherey-Nagel Inc., Bethlehem, PA) using the SuperScript III First-Strand 
Kit (#18080-051, Invitrogen Corporation), with random hexamer priming and following the 
manufacturer’s instructions. Real-time PCR was carried out with the SYBR GreenER™ qPCR 
SuperMix for iCycler® instrument (#11761-500; Invitrogen Corporation). hGAPDH 
(NM_002046) and mGAPDH (NM_008084) were used as reference and were amplified with the 
following primer pairs, respectively: hGAPDH-FWD: CATCTTCCAGGAGCGAGATCCC; 
hGAPDH-REV: TTCACACCCATGACGAACAT; mGAPDH-FWD: 
TTCACCACCATGGAGAAGGC; mGAPDH-REV: GGCATGGACTGTGGTCATGA. 
hLaminA/C (NM_170707) and E6/E7 of HPV16 (FJ610149) were amplified with the following 
primer pairs, respectively: Lamin-FWD: AGCAAAGTGCGTGAGGAGTT; Lamin-REV: 
GAGTTCAGCAGAGCCTCCAG; E6-FWD: TTGCTTTTCGGGATTTATGC; E6-REV: 
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CAGGACACAGTGGCTTTTGA. Each amplicon was sequence verified and used to generate a 
standard curve for the quantification of gene expression. 
 
Detection of cytokines. Human IFN-α in culture supernatants was quantified by sandwich ELISA 
using mouse monoclonal (0.5 µg/ml, #21112-1, PBL Biomedical, Piscataway, NJ) and rabbit 
polyclonal antibodies (0.5 µg/ml, #31130-1, PBL Biomedical). A goat anti-rabbit HRP-
conjugated antibody (0.8 µg/ml, #31460, Pierce, Rockford, IL) was used for detection. Human 
and mouse TNF-α were measured using the BD OptEIA ELISA sets (#555212 and #558874, 
respectively, BD Biosciences). In both IFN-α and TNF-α ELISAs, TMB substrate (#T0440, 
Sigma Aldrich, St. Louis, MO) was used for quantification of the cytokines on a Fluostar 
OPTIMA (BMG LABTECH, Offenburg, Germany) plate-reader. For the Bio-Plex human 
cytokine 17-plex panel (#171-A11171, Bio-Rad laboratories, Hercules, CA), the assays were 
performed following the manufacturer’s guidelines. A standard curve was generated for each 
cytokine using a five-parameter logistic regression curve fit and analyzed concentrations were 
determined automatically using Bio-Plex Manager software (v4.01). All results below the 
detectable limit were recorded as zero, and those above the standard curve were assigned a value 
equal to the top standard. 
 
Fluorescent-based measure of EGFP knockdown. EGFP expression (and down-regulation) in 
HEK 293T-GFP cells was measured using a Fluostar OPTIMA plate-reader. RNAi experiments 
were performed in 96-well black plates with clear bottoms (#353948, BD Biosciences Falcon). 
48 hours after siRNA treatment, the supernatants were discarded and 50 µl of PBS was added to 
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the cells. A standard curve was generated by serially diluting a recombinant EGFP-fusion protein 
(gift from D. Wang, Monash Institute of Medical Research, Melbourne, Australia) to cover a 
range from 150 ng/ml to 4.68 ng/ml in 50 µl PBS. The equivalent EGFP concentration in each 
well was then inferred from the fluorescence at ex485/em520 correlated to the standard curve. 
 
β-galactosidase enzymatic assay. 300,000 HEK 293T cells were reverse transfected with 300 ng 
of pLenti4/TO/V5-GW/lacZ  (Invitrogen Corporation) complexed to 1 µl of Lipofectamine 2000 
in 100 µl of Opti-MEM, in a well of a 6-well plate.  16 hours post-transfection, the cells were 
collected with 300 µl TrypLE™ Express Stable Trypsin (#12604-021; Invitrogen Corporation) 
and 1.5 ml of antibiotic-free DMEM was added. The siRNA mixes were prepared as indicated in 
the RNA interference by reverse transfection section, and 150 µl of cells were added per well, 
giving a final volume of 200 µl at 10 nM. The cells were further incubated for 24 hours before 
being lysed for 20 minutes in 40 µl of 1x Reporter Lysis Buffer (#E2000, Promega, Madison, 
WI) per well. 40 µl of the 2x assay buffer was added per well, and the plate was incubated for 30-
45 minutes at 37°C.  The enzymatic reaction was stopped with the addition of 40 µl sodium 
carbonate (1 M), and the plate was read at 440 nm on a Fluostar OPTIMA plate-reader. 
 
SFV viral assay. Hela cells were seeded into 96-well plates and incubated overnight at 37°C to 
reach ~100% confluency. The cells were treated with 100 µl of supernatant from siRNA-treated 
PBMCs. A ¼ serial dilution of the conditioned media was performed for each of the siRNA 
treatments. Following a 4 hour pre-treatment with conditioned media, the cells were washed and 
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infected with 100 µl of DMEM (10% FBS) containing 200 pfu/ml of SFV. The cells were 
incubated with the virus for 36 hours before being rinsed with PBS and fixed with 10% formalin 
for 30 minutes. The cells were further stained for 30 minutes with 0.05% crystal violet in 20% 
ethanol, before thorough H2O washes and reading at 590 nm on a Fluostar OPTIMA plate reader. 
 
Statistical analyses. Statistical analyses were carried out using GraphPad Instat version 3.05. 
(GraphPad Software Inc., La Jolla, CA). Two-tailed unpaired T-tests or non-parametric Mann-
Whitney tests were used according to the standard deviation of the compared populations. Error 
bars on each figure represent the standard error of the mean. Symbols used: * P≤0.05, ** P≤0.01, 
*** P≤0.0001 and NS is non-significant. 
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SUPPLEMENTARY MATERIAL 
Supplementary Figure S1  Immunostimulation of siRNA targeting Bcl2L12. 
The native human Bcl2L12 (NM_138639) siRNA is inherently immunostimulatory. Human 
PBMCs were treated with indicated concentration of indicated siRNA complexed with DOTAP 
and incubated for 16 hours at 37°C. TNF-α concentration was measured by ELISA.  The data is 
averaged from two independent experiments in biological triplicate from two blood donors. 
 
Supplementary Table S1  Sequences of dsRNAs used in the study 
 
Name Sequence 
siβ-Gal-924 5’     UUAUGCCGAUCGCGUCACAtt 3’ 
3’   ttAAUACGGCUAGCGCAGUGU 5’ 
 
siβ-Gal-924-U 5’     UUAUGCCGUUUUCGUCACAtt 3’ 
3’   ttAAUACGGCUAGCGCAGUGU 5’ 
  
siBcl2L12 5’   GCUGGUCCGCCUGUCCUCCGACUCU 3’ 
3’ UUCGACCAGGCGGACAGGAGGCUGAGA 5’ 
 
siBcl2L12-U 5’   GCUGGUCCUUUUGUCCUCCGACUCU 3’ 
3’ UUCGACCAGGCGGACAGGAGGCUGAGA 5’ 
 
The uridine-bulge is highlighted in bold and the non-matching residues are underlined. 
Uppercase letters are RNA bases and lowercase letters are DNA bases. 
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Table 1  Sequences of ssRNAs used in the study 
 
Name Sequence dG 
B-406AS 5’UAAUUCGCGUCUGGCCUUCUU 3’ -0.5 
B-406AS-1 5’UAGUUGGCCUCUGGCCUUCUU 3’ -5.6 
B-406AS-2 5’UAGUUGGCGUCUGGCCUUCUU 3’ -4.0 
B-406AS-3 5’UAAUUGGCGUCUGGCCUUCUU 3’ -3.9 
ss41-N (Native) 5’GCCCGACAGAAGAGAGACAC 3’ - 
ss41-L (Loop) 5’GCCGGACAGAAGAGAGACGC 3’ 1.3 
ss41-2 5’GCCGGACAUUAGAGAGACGC 3’ 1.3 
ss41-4 5’GCCGGACAUUAUAUAGACGC 3’ 1.3 
ss41-6 5’GCCGGACAUUAUUUAUACGC 3’ 1.3 
ss41-8 5’GCCGGUCUUUAUUUAUACGC 3’ 1.3 
ss41-10 5’GCCGGUCUUUUUUUUUACGC 3’ 1.3 
 
The modifications to the native sequences (either B-406AS or ss41-Native) are highlighted in 
bold. 
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Figure 1  Relative immunostimulation of ssRNAs with sequence or structural alterations. 
(a) and (c) mFOLD-predicted structure of ssRNAs.37  All ss41-RNAs have a similar predicted 
secondary structure and only ss41-loop and ss41-8 are presented here. The amount of uridines in 
the ss41 series is indicated by the x in the ss41-x name. Predicted free-energy of the loops is 
indicated with dG value. ss41-Native does not have a predicted secondary structure. All 
sequences are shown in Table 1. (b) and (d)  Immunostimulation of ssRNAs in human PBMCs 
treated with 90 nM of indicated ssRNA complexed with DOTAP and incubated for 16 hours at 
37°C. Cytokine production was measured by specific ELISA as described in Materials and 
Methods. The data is averaged from (b) three independent experiments in biological triplicate 
from four blood donors and (d) two independent experiments in biological triplicate from three 
blood donors. (b) Unpaired two-tailed T-test and non-parametric two-tailed Mann-Whitney test 
were used for IFN-α and TNF-α statistical comparison compared with B-406-AS, respectively. 
NS: non-significant. 
 
Figure 2  Rational design of immunotimulatory siRNA scaffold. 
(a) Overview of design approach. siLam-N is the original siRNA sequence targeting the 
LaminA/C mRNA. Watson-Crick base-pairing is shown with a “|” symbol, while G:U wobble 
pairing is indicated with a dot. The target-specific sequence of the guide strand is in italics, and 
the “GU” immunostimulatory motifs added to the native sequence are in bold. (b) 
Immunostimulation of siRNAs in human PBMCs treated with 600 nM of siRNA complexed with 
DOTAP and incubated for 16 hours at 37°C. Cytokine production was measured by specific 
ELISA. The data is averaged from three independent experiments in three different blood donors. 
Unpaired two-tailed non-parametric Mann-Whitney tests are versus siLam-N. (c) Knockdown 
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efficiency of siRNAs transfected in HEK 293 cells at a final concentration of 10 nM. After 24 
hours at 37°C, total RNA was extracted and reverse-transcribed as described in Material and 
Methods. LaminA/C mRNA expression was assessed by quantitative real time PCR, and reported 
to that of GAPDH. The data is expressed as percentage of fold expression of siControl, and is 
averaged from two independent experiments in biological triplicate. Unpaired two-tailed T-test is 
presented using siLam-N as a reference. 
 
Figure 3  Validation of uridine -bulge siRNA design scaffold. 
(a) and (c) Human PBMCs were treated with indicated concentration of specified siRNA 
complexed with DOTAP and incubated for 16 hours at 37°C. Cytokine production was measured 
by specific ELISA. (a) The data is averaged from four independent experiments in four blood 
donors. Unpaired two-tailed non-parametric Mann-Whitney tests are shown. (b) RNAi efficiency 
of EGFP siRNAs. HEK 293 cells stably expressing EGFP were transfected with 10 nM of 
indicated siRNA for ~48 hours. EGFP production was assayed in fluorescent plate reader as 
described in Materials and Methods. The data is presented as the EGFP protein concentration 
relative to that of the Mock transfected control, and is averaged from three independent 
experiments in biological triplicate. siGFP19+2 is a 21 bp siRNA targeting EGFP.4 Unpaired 
two-tailed T-test is presented using siEGFP-U as a reference. (c) The data is averaged from two 
blood donors in biological triplicate and is representative of two independent experiments. 
Unpaired two-tailed non-parametric Mann-Whitney tests are shown. (d) Knockdown efficiency 
of siRNAs transfected in Murine TC-1 cells at a final concentration of 10 nM. After 24 hours at 
37°C, total RNA was extracted and reverse-transcribed as described in Materials and Methods. 
The E6/E7 mRNA was assessed by quantitative real time PCR, and presented relative to that of 
mouse GAPDH. The data is expressed as percentage fold expression of siControl, and is averaged 
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from two independent experiments in biological triplicate. Unpaired two-tailed T-test comparing 
siE6/E7 and siE6/E7-U is shown using siE6/E7 as a reference.  (e) Details of siEGFP and 
siE6/E7 designs. Watson-Crick base-pairing is shown with a “|” symbol, the 19 nt target-specific 
sequence of the guide strand is in italics, and the “U” bulge immunostimulatory motifs added to 
the native sequences are in bold. 
 
Figure 4  Species-specific response to the uridine-bulge. 
(a) FACS-purified CD14+ human monocytes and (b) mouse BMMs were stimulated with (a) 500 
nM (b) or indicated concentration of specified siRNA complexed with DOTAP and incubated for 
16 hours at 37°C. Cytokine production was measured by specific ELISA. (a) The data is 
averaged from two independent experiments in biological triplicate in two blood donors. 
Unpaired two-tailed non-parametric Mann-Whitney test comparing siEGFP and siEGFP-U is 
shown. (b) The data is representative of two independent experiments in biological triplicate. 
 
Figure 5  Immunostimulatory profile of uridine-bulge modification. 
(a)-(d) PBMCs from two blood donors were treated with 750 nM of indicated siRNA complexed 
with DOTAP in biological duplicate and incubated for 16 hours at 37°C. Cytokine concentrations 
were measured using 50 µl of supernatants with a 17 cytokines bead-array (BioRad) on a Bioplex 
platform. The data is averaged from two blood donors in biological duplicate, giving four data 
points per condition. Unpaired two-tailed T-tests were carried out for each siRNA pair, with or 
without the uridine modification. 
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Figure 6  Antiviral effects of the uridine-bulge-driven increased immunostimulation. 
Human PBMCs were treated overnight with DOTAP-complexed siEGFP and its uridine-bulge 
variant (at 750 nM), and the supernatants collected. 100% confluent Hela cells were pre-treated 
with the resulting conditioned media for 4 hours, prior to infection with SFV, as described in 
Materials and Methods. Following 36 hours at 37°C, the cells were fixed, stained with crystal 
violet, and relative absorbance measured. Cell survival inversely correlates with viral activity, 
thereby resulting in increased absorbance readings when the antiviral effect is greater. The data is 
averaged from four independent viral assays, from two blood donors. Unpaired two-tailed T-test 
is presented comparing siEGFP and siEGFP-U conditions. 
 
Figure 7  Conserved RNAi efficiency, but not increased immunostimulation, depends on the 
siRNA scaffold. 
(a) Human PBMCs were treated with indicated concentration of specified siRNA complexed 
with DOTAP and incubated for 16 hours at 37°C. Cytokine production was measured by specific 
ELISA. The data is averaged from two blood donors in biological triplicate and is representative 
of two independent experiments. (b) HEK 293T cells were transfected with pLenti4/TO/V5-
GW/lacZ for 16 hours at 37°C prior to transfection with 10 nM of indicated siRNA. 24 hours 
post-siRNA transfection, the cells were lysed and assayed for β-galactosidase activity as 
described in Materials and Methods. The data is averaged from two independent experiments in 
biological triplicate and expressed as percentage of the β-galactosidase activity of the Mock 
condition. Unpaired two-tailed T-test is presented compared to siβ-Gal-924. 
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